Researching investing ideas in biodefense stocks? Look no further! Investorideas.com offers a free stock directory to help you get started.
Investors and traders, sign up for news alerts and make this your starting point for investing in these biodefense stocks.
For public biodefense companies - If your company is listed, you can request to update your description. Not listed? Email us to learn more about our services and how we can help tell your story to investors in the sector.
Premium Listing ($2,500/year)
Description: A one-year enhanced listing with additional features to boost visibility and engagement, targeting companies seeking investor attention.
Features:
Aethlon Medical, Inc. NasdaqCM: AEMD
Aethlon Medical develops the Hemopurifier, a device to remove life-threatening viruses for biodefense and infectious disease treatment. In Q1 2025, Aethlon advances FDA trials for Hemopurifier against bioterrorism-related viruses, targeting breakthrough status. The company's technology addresses critical public health emergencies.
Altimmune, Inc. NasdaqGM: ALT
Altimmune develops intranasal vaccines, including an anthrax vaccine candidate for biodefense applications. In Q1 2025, Altimmune progresses its intranasal anthrax vaccine trials with U.S. government funding for bioterrorism preparedness. The company's platform ensures rapid protection against biological threats.
Appili Therapeutics Inc. TSX: APLI.TO
Appili Therapeutics develops vaccines and therapeutics for infectious diseases, with ATI-1701 targeting Francisella tularensis for biodefense. In Q1 2025, Appili advances ATI-1701's Phase 1 trials with U.S. Department of Defense support, strengthening bioterrorism countermeasures. The company's focus on priority pathogens drives public health security.
Arcturus Therapeutics Holdings Inc. NasdaqGM: ARCT
Arcturus Therapeutics develops mRNA vaccines for infectious diseases, including ARCT-154 for COVID-19 with biodefense potential. In Q1 2025, Arcturus advances ARCT-154's global trials, supported by BARDA funding for pandemic preparedness. The company's mRNA platform strengthens defenses against viral threats.
Bavarian Nordic A/S OMX: BAVA.CO
Bavarian Nordic develops vaccines for smallpox, mpox, and Ebola, with JYNNEOS approved for biodefense against smallpox and mpox. In Q1 2025, Bavarian Nordic expands JYNNEOS production for global health agencies, addressing bioterrorism threats. The company's robust vaccine platform safeguards against infectious disease outbreaks.
BioCryst Pharmaceuticals, Inc. NasdaqGS: BCRX
BioCryst develops antiviral therapeutics, including galidesivir for biodefense against filoviruses like Ebola and Marburg. In Q1 2025, BioCryst advances galidesivir's preclinical studies with U.S. government funding, targeting bioterrorism preparedness. The company's oral antivirals enhance rapid-response capabilities for infectious threats.
BioNTech SE NasdaqGS: BNTX
BioNTech develops mRNA vaccines for infectious diseases, including Comirnaty for COVID-19 and biodefense-relevant candidates. In Q1 2025, BioNTech advances mRNA vaccines for emerging viral threats, partnering with global health organizations. The company's rapid-response platform strengthens pandemic and bioterrorism defenses.
Chimerix, Inc. NasdaqCM: CMRX
Chimerix develops antiviral therapeutics, with brincidofovir (TEMBEXA) for smallpox biodefense. In Q1 2025, Chimerix supports mpox trials for brincidofovir in Africa, enhancing bioterrorism preparedness. The company's antivirals address critical public health threats.
Cleveland BioLabs, Inc. OTCQB: CBLI
Cleveland BioLabs develops entolimod, a biodefense therapeutic for acute radiation syndrome with potential infectious disease applications. In 2025, Cleveland BioLabs advances entolimod's preclinical studies, supported by U.S. government biodefense funding. The company's immunomodulatory platform strengthens responses to biological threats.
Dynavax Technologies Corporation NasdaqGS: DVAX
Dynavax develops CpG 1018 adjuvant-based vaccines for biodefense, including anthrax and plague candidates. In Q1 2025, Dynavax secures U.S. government contracts to advance its anthrax vaccine program. The company's adjuvant technology enhances biodefense vaccine efficacy.
Emergent BioSolutions Inc. NYSE: EBS
Emergent BioSolutions produces anthrax vaccines (BioThrax, CYFENDUS), smallpox antivirals (TEMBEXA), and Ebola therapeutics (Ebanga) for biodefense. In Q1 2025, Emergent secures U.S. government contracts to expand anthrax and smallpox vaccine stockpiles. The company's biodefense portfolio is critical for national security and global health.
GeoVax Labs, Inc. NasdaqCM: GOVX
GeoVax develops vaccines for Ebola, Lassa fever, and mpox, with GEO-MVA targeting biodefense applications. In Q1 2025, GeoVax advances GEO-MVA's Phase 2 trials, funded by U.S. biodefense grants. The company's MVA platform addresses high-priority bioterrorism threats.
Gilead Sciences, Inc. NasdaqGS: GILD
Gilead Sciences develops antivirals like remdesivir for Ebola and COVID-19, addressing biodefense and infectious disease outbreaks. In Q1 2025, Gilead advances remdesivir's applications for emerging viral threats, supporting global health preparedness. The company's antiviral expertise bolsters defenses against bioterrorism.
Inovio Pharmaceuticals, Inc. NasdaqGS: INO
Inovio develops DNA-based vaccines for infectious diseases, including Ebola and Lassa fever with biodefense applications. In Q1 2025, Inovio progresses INO-4201's Phase 1 trials for Ebola, funded by U.S. biodefense programs. The company's DNA platform enables rapid vaccine deployment against biological threats.
Merck & Co., Inc. NYSE: MRK
Merck develops vaccines for Ebola (ERVEBO) and other infectious diseases with biodefense applications. In Q1 2025, Merck expands ERVEBO's global distribution, supporting WHO stockpiles for outbreak response. The company's vaccine expertise strengthens biodefense preparedness.
Moderna, Inc. NasdaqGS: MRNA
Moderna pioneers mRNA vaccines, with Spikevax for COVID-19 and candidates for biodefense-relevant viruses like RSV and Ebola. In Q1 2025, Moderna advances its mRNA-1345 RSV vaccine and explores biodefense applications, nearing FDA approval. The company's rapid-response mRNA technology strengthens global pandemic preparedness.
Novavax, Inc. NasdaqGS: NVAX
Novavax develops protein-based vaccines, including NVX-CoV2373 for COVID-19 and candidates for influenza with biodefense potential. In Q1 2025, Novavax expands its COVID-19/influenza combination vaccine trials, supporting global health security. The company's vaccine platform addresses emerging infectious disease threats.
Parsons Corporation NYSE: PSN
Parsons Corporation supports biodefense through rapid infectious disease detection and global surveillance for the Naval Medical Research Command. In Q1 2025, Parsons secures a $24 million NMRC contract to advance pathogen detection, enhancing U.S. military preparedness. The company's expertise in molecular biology strengthens bioterrorism countermeasures.
Pfizer Inc. NYSE: PFE
Pfizer develops vaccines and antivirals, including Comirnaty for COVID-19 and biodefense-relevant candidates for emerging pathogens. In Q1 2025, Pfizer expands its mRNA vaccine platform for rapid response to bioterrorism-related viruses. The company's global infrastructure supports biodefense preparedness.
SIGA Technologies, Inc. NasdaqGM: SIGA
SIGA Technologies develops TPOXX (tecovirimat), an antiviral for smallpox and orthopoxviruses, critical for biodefense. In Q1 2025, SIGA secures additional U.S. government contracts for TPOXX stockpiling, enhancing bioterrorism preparedness. The company's antiviral solutions protect against high-risk biological threats.
Soligenix, Inc. NasdaqCM: SNGX
Soligenix develops vaccines for biodefense, including RiVax for ricin toxin and filovirus vaccines for Ebola and Marburg. In 2025, Soligenix advances RiVax's Phase 1 trials with U.S. government funding, targeting bioterrorism countermeasures. The company's vaccine portfolio strengthens global health security.
Tonix Pharmaceuticals Holding Corp. NasdaqCM: TNXP
Tonix Pharmaceuticals develops TNX-801, a smallpox and mpox vaccine candidate for biodefense applications. In Q1 2025, Tonix progresses TNX-801's preclinical trials, supported by U.S. biodefense grants. The company's platform addresses critical bioterrorism and infectious disease threats.
Vaxart, Inc. NasdaqCM: VXRT
Vaxart develops oral vaccines for COVID-19 and norovirus, with biodefense applications for rapid-deployment vaccination. In Q1 2025, Vaxart advances its oral COVID-19 vaccine trials, supported by BARDA funding for pandemic preparedness. The company's tablet-based platform enhances biodefense response capabilities.
XOMA Corporation NasdaqGM: XOMA
XOMA develops antibodies for biodefense, including XOMA 3AB for botulism and other infectious threats. In Q1 2025, XOMA licenses its anti-botulism antibodies to government partners, advancing bioterrorism countermeasures. The company's antibody platform supports public health preparedness.
Our site does not give specific recommendations and encourages investors to complete their own due diligence. Our lists are compiled from internal and external research sources. Our lists are to be used only as a partial source of due diligence.
